MALATESTA, SARA
 Distribuzione geografica
Continente #
NA - Nord America 671
EU - Europa 541
AS - Asia 373
SA - Sud America 28
OC - Oceania 2
AF - Africa 1
Totale 1.616
Nazione #
US - Stati Uniti d'America 666
SG - Singapore 139
CN - Cina 128
UA - Ucraina 93
IE - Irlanda 91
IT - Italia 70
SE - Svezia 66
GB - Regno Unito 63
TR - Turchia 58
FR - Francia 55
DE - Germania 42
IN - India 37
BR - Brasile 25
FI - Finlandia 21
RU - Federazione Russa 19
BE - Belgio 5
CZ - Repubblica Ceca 5
CA - Canada 4
HK - Hong Kong 4
IL - Israele 3
AT - Austria 2
AU - Australia 2
CL - Cile 2
VN - Vietnam 2
BY - Bielorussia 1
CH - Svizzera 1
CO - Colombia 1
ES - Italia 1
GR - Grecia 1
LB - Libano 1
LI - Liechtenstein 1
LT - Lituania 1
MX - Messico 1
NL - Olanda 1
NO - Norvegia 1
PK - Pakistan 1
PL - Polonia 1
ZA - Sudafrica 1
Totale 1.616
Città #
Chandler 143
Singapore 111
Jacksonville 103
Dublin 91
Southend 52
Beijing 36
Princeton 36
Nanjing 34
Ashburn 32
Izmir 32
The Dalles 25
Santa Clara 20
Altamura 18
Cambridge 18
Boardman 17
Dearborn 16
Ann Arbor 14
Wilmington 12
Nanchang 11
New York 11
Los Angeles 8
Munich 8
Tianjin 7
Helsinki 6
Shenyang 6
Woodbridge 6
Brussels 5
Hangzhou 5
Hebei 5
Kunming 5
Collecorvino 4
Hong Kong 4
Milan 4
Washington 4
Brno 3
Orange 3
Squinzano 3
Tappahannock 3
Aprilia 2
Changchun 2
Changsha 2
Council Bluffs 2
Dong Ket 2
Edinburgh 2
Fairfield 2
Grevenbroich 2
Jinan 2
Ningbo 2
Norwalk 2
Ottawa 2
São Paulo 2
Toronto 2
Zhengzhou 2
Andover 1
Augusta 1
Barbosa 1
Beirut 1
Boston 1
Brdo 1
Brisbane 1
Buffalo 1
Campinas 1
Campo Verde 1
Canzano 1
Charlotte 1
Chieti 1
Chongqing 1
Civitanova Marche 1
Clearwater 1
Cubatão 1
Eden Prairie 1
Faisalabad 1
Frankfurt am Main 1
Guarulhos 1
Hefei 1
Itaperuna 1
Jiaxing 1
Johannesburg 1
Juiz de Fora 1
Kemerovo 1
Kraków 1
Kyiv 1
Lanzhou 1
Las Vegas 1
Laurel 1
Leawood 1
London 1
Malacacheta 1
Manhuaçu 1
Marília 1
Mexico City 1
Mococa 1
Mossoró 1
New Delhi 1
Novo Hamburgo 1
Olomouc 1
Orlando 1
Osvaldo Cruz 1
Palermo 1
Perm 1
Totale 998
Nome #
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 126
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 122
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 118
A unique microRNA signature associated with plaque instability in humans. 111
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. 109
A unique microRNA signature associated with ischemic stroke in humans 107
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 98
HIGH-RISK HUMAN PAPILLOMA VIRUS INFECTION, TUMOR PATHOPHENOTYPES AND BRCA1/2 AND P53 STATUS IN JUVENILE BREAST CANCER PATIENTS. 94
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 88
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 84
Mutational profile of GNAQQ209 in human tumors. 82
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 79
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 77
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 76
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 76
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 72
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 72
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 67
Totale 1.658
Categoria #
all - tutte 6.804
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.804


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202045 0 0 0 0 0 0 0 0 0 0 44 1
2020/2021112 20 0 23 2 8 22 0 2 10 15 5 5
2021/202286 2 1 1 20 2 1 0 7 8 11 10 23
2022/2023364 25 57 18 46 41 63 15 23 48 2 13 13
2023/2024168 14 1 12 4 7 57 35 10 0 4 0 24
2024/2025338 16 83 78 10 8 25 3 9 40 27 39 0
Totale 1.658